Gastroesophageal Cancer (GC)
Oncology·MeSH: Ovarian Neoplasms
Prevalence
13.9 / 100K
Incidence
8.0 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| CTX-10726 | Compass Therapeutics, Inc. (CMPX) |
Frequently asked questions
How many drugs are in development for Gastroesophageal Cancer (GC)?
BioSniper tracks 1 drug in development for Gastroesophageal Cancer (GC) across 1 company.
How many clinical trials target Gastroesophageal Cancer (GC)?
There are 3 clinical trials targeting Gastroesophageal Cancer (GC) tracked by BioSniper.
What is the prevalence of Gastroesophageal Cancer (GC)?
The estimated prevalence of Gastroesophageal Cancer (GC) is approximately 13.9 per 100,000 population.
Deep-dive into Gastroesophageal Cancer (GC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis